Skip to main content

Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection

Graefe's Archive for Clinical and Experimental Ophthalmology volume 255, pages 2271–2276 (2017)Cite this article

Abstract

Purpose

The purpose of this study was to report the clinical outcomes of patients with conjunctival melanoma treated with interferon (IFN) α-2b eye drops following local tumor resection.

Methods

Five eyes of five patients were enrolled in this study. All patients underwent the local resection of tumors, and topical IFNα-2b eye drops were subsequently administered 4 times/day until the complete disappearance of the pigmented lesions determined by slit-lamp examination. Ophthalmological findings, histopathological findings, and imaging modalities were retrospectively analyzed.

Results

The age of the patients ranged from 65 to 84 years (mean: 75.4 years). Locations of the tumor were the bulbar conjunctiva in three eyes, multiple palpebral conjunctivas in one eye, and palpebral conjunctiva and caruncle in one eye. All patients received topical IFNα-2b eye drop treatment for 6–10 months. Follow-up periods after resection ranged from 18 to 78 months. Histologically, all excised conjunctival tumors were diagnosed with malignant melanoma, where the surgical margins were completely negative in one patient. No patients had suffered from severe adverse effects related to IFNα-2b. Four out of five patients consequently achieved complete remission. Since one eye in one case showed resistance to the local chemotherapy containing IFNα-2b eye drops and the subconjunctival injection of IFN-β, orbital exenteration was eventually required 12 months after local resection.

Conclusions

Topical IFNα-2b eye drops may be safe and one of the useful adjunctive treatments following surgical resection for patients with conjunctival melanoma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Paridaens AD, Minassian DC, McCartney AC, Hungerford JL (1994) Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol 78:252–259

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. Norregaard JC, Gerner N, Jensen OA, Prause JU (1996) Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol 234:569–572

    CAS  Article  PubMed  Google Scholar 

  3. Shields CL, Shields JA, Gunduz K, Cater J, Mercado GV, Gross N, Lally B (2000) Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol 118:1497–1507

    CAS  Article  PubMed  Google Scholar 

  4. Wuestemeyer H, Sauerwein W, Meller D, Chauvel P, Schueler A, Steuhl KP, Bornfeld N, Anastassiou G (2006) Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol 244:438–446

    Article  PubMed  Google Scholar 

  5. Finger PT, Milner MS, McCormick SA (1993) Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol 77:751–753

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119–134

    CAS  Article  PubMed  Google Scholar 

  7. Kirkwood J (2002) Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29:18–26

    CAS  Article  PubMed  Google Scholar 

  8. Singh M, Gautam N, Gupta A, Kaur M (2016) Interferon alfa-2b in the management of recurrent conjunctival papillomatosis. Indian J Ophthalmol 64:778–780

    Article  PubMed  PubMed Central  Google Scholar 

  9. Schechter BA, Rand WJ, Velazquez GE, Williams WD, Starasoler L (2002) Treatment of conjunctival papillomata with topical interferon Alfa-2b. Am J Ophthalmol 134:268–270

    CAS  Article  PubMed  Google Scholar 

  10. Karp CL, Galor A, Chhabra S, Barnes SD, Alfonso EC (2010) Subconjunctival/perilesional recombinant interferon alpha 2b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology 117:2241–2246

    Article  PubMed  Google Scholar 

  11. Karp CL, Galor A, Lee Y, Yoo SH (2010) Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: a pilot study. Ocul Immunol Inflamm 18:254–260

    CAS  Article  PubMed  Google Scholar 

  12. Endo H, Kase S, Suzuki Y, Kase M (2016) Coincidence of inflamed Conjunctival carcinoma in situ and primary Pterygium. Case Rep Ophthalmol 7:208–212

    Article  PubMed  PubMed Central  Google Scholar 

  13. Herold TR, Hintschich C (2010) Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol 248:111–115

    CAS  Article  PubMed  Google Scholar 

  14. Finger PT, Sedeek RW, Chin KJ (2008) Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol 145:124–129

    CAS  Article  PubMed  Google Scholar 

  15. Garip A, Schaumberger MM, Wolf A, Herold TR, Miller CV, Klingenstein A, Schebitz-Walter K, Hintschich CR (2016) Evaluation of a short-term topical interferon alpha-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia. Orbit 35:29–34

    Article  PubMed  Google Scholar 

  16. Kase S, Ishijima K, Noda M, Ishida S (2011) Two cases of conjunctival malignant melanoma treated with topical interferon alpha-2b drop as an adjuvant therapy. Nippon Ganka Gakkai Zasshi 115:1043–1047

    PubMed  Google Scholar 

  17. Poothullil AM, Colby KA (2006) Topical medical therapies for ocular surface tumors. Semin Ophthalmol 21:161–169

    Article  PubMed  Google Scholar 

  18. Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT (1998) Antimetabolite-induced apoptosis in Tenon’s capsule fibroblasts. Invest Ophthalmol Vis Sci 39:449–454

    CAS  PubMed  Google Scholar 

  19. Shields JA, Shields CL, De Potter P (1998) Surgical management of circumscribed conjunctival melanomas. Ophthal Plast Reconstr Surg 14:208–215

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo, 060-8638, Japan

    Iku Kikuchi, Satoru Kase, Kan Ishijima & Susumu Ishida

Authors
  1. Iku Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoru Kase
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kan Ishijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Susumu Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoru Kase.

Ethics declarations

Funding

No funding was received for this research.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Informed consent

For this type of study formal consent is not required.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kikuchi, I., Kase, S., Ishijima, K. et al. Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection. Graefes Arch Clin Exp Ophthalmol 255, 2271–2276 (2017). https://doi.org/10.1007/s00417-017-3754-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-017-3754-2

Keywords

  • Conjunctival melanoma
  • Interferon alpha-2b
  • Eye drop
  • Remission